Tingxiu Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tingxiu Zhao has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Bo Liu
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications - Jianyong Xiao
Department of Biochemistry Guangzhou University of Chinese Medicine Guangzhou China
3 shared publications - Kun Wang
Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications Yunshan Wu
The Second Clinical Medical College, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Guangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangzhou, 510006, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangzhou, 510006, China
3 shared publications- Bonan Chen
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Sir Y.K. Pao Cancer Center, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
2 shared publications Haoxiang Li
The second Clinical Medical College, Chinese Medicine Guangdong laboratory, and Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
2 shared publications
Latest Publications
- 11 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118474
Target validation and drug discovery for TNBC: Targeting the Lin28B/Let-7/PBK with the ponicidin
- 11 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118474
Target validation and drug discovery for TNBC: Targeting the Lin28B/Let-7/PBK with the ponicidin
- 9 November 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157507
Sanqi Qushi formula alleviates podocyte damage in passive Heymann Nephritis rats by inhibiting GPX4 deficiency-mediated ferroptosis via the JNK/FoxO1 signaling pathway
- 9 November 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157507
Sanqi Qushi formula alleviates podocyte damage in passive Heymann Nephritis rats by inhibiting GPX4 deficiency-mediated ferroptosis via the JNK/FoxO1 signaling pathway
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45794
Association between frailty and gout in middle-aged and older adults: A nationwide cross-sectional and Mendelian randomization study
With the aging population, frailty is becoming increasingly prevalent among older adults, yet its association with gout, a common form of arthritis affecting middle-aged and older adults, remains unclear. This study investigated the frailty-gout relationship through a nationwide cross-sectional analysis combined with Mendelian randomization (MR). Data from 22,324 adults aged 40 and above in the National Health and Nutrition Examination Survey (NHANES, 2007–2018) were analyzed utilizing survey-weighted logistic regression models. Genome-wide association study data from UK Biobank, TwinGen, and FinnGen were utilized to explore genetic correlations and causality. The cross-sectional study indicated a significant relationship between pre-frail (odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.76–3.08, P < .0001) and frail (OR = 4.63, 95% CI = 3.67–5.84, P < .0001) individuals and gout. This association persisted after comprehensive covariate adjustment (pre-frail OR = 2.13, 95% CI = 1.59–2.85, P < .0001; frail OR = 4.11, 95% CI = 3.16–5.35, P < .0001). The interaction effect between frailty and gout was significantly influenced by race/ethnicity ( P interaction = .0046) and gender ( P interaction = 6.72 × 10 −6 ). Linkage disequilibrium score regression analysis demonstrated a moderate yet significant genetic correlation between the frailty index and gout ( r g = 0.319, standard error (SE) = 0.042, P = 2.19 × 10 −14 ). MR analysis confirmed a causal link between frailty index and gout (OR = 2.29, 95% CI = 1.45–3.62, P < .001), while reverse MR analysis indicated no causality. These findings elucidated frailty as a risk factor for gout, underscoring the necessity for uric acid monitoring to mitigate gout risk in frail individuals, potentially informing sustained healthcare initiatives for gout in middle-aged and older adults.
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45794
Open AccessAssociation between frailty and gout in middle-aged and older adults: A nationwide cross-sectional and Mendelian randomization study
With the aging population, frailty is becoming increasingly prevalent among older adults, yet its association with gout, a common form of arthritis affecting middle-aged and older adults, remains unclear. This study investigated the frailty-gout relationship through a nationwide cross-sectional analysis combined with Mendelian randomization (MR). Data from 22,324 adults aged 40 and above in the National Health and Nutrition Examination Survey (NHANES, 2007–2018) were analyzed utilizing survey-weighted logistic regression models. Genome-wide association study data from UK Biobank, TwinGen, and FinnGen were utilized to explore genetic correlations and causality. The cross-sectional study indicated a significant relationship between pre-frail (odds ratio [OR] = 2.33, 95% confidence interval [CI] = 1.76–3.08, P < .0001) and frail (OR = 4.63, 95% CI = 3.67–5.84, P < .0001) individuals and gout. This association persisted after comprehensive covariate adjustment (pre-frail OR = 2.13, 95% CI = 1.59–2.85, P < .0001; frail OR = 4.11, 95% CI = 3.16–5.35, P < .0001). The interaction effect between frailty and gout was significantly influenced by race/ethnicity ( P interaction = .0046) and gender ( P interaction = 6.72 × 10 −6 ). Linkage disequilibrium score regression analysis demonstrated a moderate yet significant genetic correlation between the frailty index and gout ( r g = 0.319, standard error (SE) = 0.042, P = 2.19 × 10 −14 ). MR analysis confirmed a causal link between frailty index and gout (OR = 2.29, 95% CI = 1.45–3.62, P < .001), while reverse MR analysis indicated no causality. These findings elucidated frailty as a risk factor for gout, underscoring the necessity for uric acid monitoring to mitigate gout risk in frail individuals, potentially informing sustained healthcare initiatives for gout in middle-aged and older adults.
- Open Access
- 20 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt B) , 120453
Sanqi qushi formula ameliorates podocyte injury in membranous nephropathy by inhibiting endoplasmic reticulum stress-induced ferroptosis
- 20 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt B) , 120453
Open AccessSanqi qushi formula ameliorates podocyte injury in membranous nephropathy by inhibiting endoplasmic reticulum stress-induced ferroptosis
- Open Access
- 27 February 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (7) , 2056-2072
Tetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation
MHC-I-mediated antigen presentation is pivotal in antitumor immunity, enabling the recognition and destruction of tumor cells by CD8+ T cells. Both the proteasome and autophagy serve as essential cellular degradation mechanisms that regulate the stability and functionality of MHC-I molecules. In melanoma, modulating the pathways that affect MHC-I antigen presentation is pivotal and can profoundly influence the therapeutic outcomes of immunotherapy. Our initial effort of this study was a screening process to identify natural compounds capable of amplifying MHC-I surface expression on B16 melanoma cells. Utilizing flow cytometry with fluorescently tagged antibodies, we identified tetrandrine (Tet), a bisbenzylisoquinoline alkaloid derived from the root of Stephania tetrandra, as a potent enhancer of MHC-I-mediated antigen presentation in B16 melanoma cells. We demonstrate that tetrandrine (2.5, 5, 7.5 μM) dose-dependently upregulates both surface and total MHC-I protein levels in B16 or A375 melanoma cells by simultaneously inhibiting autophagy and proteasomal activity, two key pathways involved in MHC-I degradation. This dual inhibition stabilizes MHC-I molecules, leading to enhanced tumor antigen presentation and improved recognition by CD8+ T cells. In co-culture systems, tetrandrine treatment increased CD8+ T cell activation and cytotoxicity against melanoma cells, evidenced by elevated IFN-γ secretion and increased tumor cell apoptosis. Administration of tetrandrine (50 mg·kg-1·d-1, i.g., for 15 days) significantly suppressed melanoma growth in mouse models accompanied by increased CD8+ T cell infiltration and activation within the tumor microenvironment. Notably, tetrandrine synergized with anti-PD-1 immune checkpoint therapy, leading to enhanced tumor growth inhibition compared to either treatment alone. We revealed that tetrandrine (7.5 μM) blocked the lysosomal calcium efflux channel TPC2, disrupting lysosomal calcium homeostasis, thus impairing lysosomal acidification and proteasomal activity, thereby stabilizing MHC-I molecules and promoting antigen presentation. These results highlight tetrandrine’s unique mechanism of action in enhancing MHC-I-mediated antigen presentation through dual inhibition of autophagic flux and proteasomal degradation. This study underscores tetrandrine’s potential as a novel immunomodulatory agent to boost CD8+ T cell-mediated tumor cell eradication and enhance the efficacy of immune checkpoint therapies.
- 27 February 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (7) , 2056-2072
Open AccessTetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation
MHC-I-mediated antigen presentation is pivotal in antitumor immunity, enabling the recognition and destruction of tumor cells by CD8+ T cells. Both the proteasome and autophagy serve as essential cellular degradation mechanisms that regulate the stability and functionality of MHC-I molecules. In melanoma, modulating the pathways that affect MHC-I antigen presentation is pivotal and can profoundly influence the therapeutic outcomes of immunotherapy. Our initial effort of this study was a screening process to identify natural compounds capable of amplifying MHC-I surface expression on B16 melanoma cells. Utilizing flow cytometry with fluorescently tagged antibodies, we identified tetrandrine (Tet), a bisbenzylisoquinoline alkaloid derived from the root of Stephania tetrandra, as a potent enhancer of MHC-I-mediated antigen presentation in B16 melanoma cells. We demonstrate that tetrandrine (2.5, 5, 7.5 μM) dose-dependently upregulates both surface and total MHC-I protein levels in B16 or A375 melanoma cells by simultaneously inhibiting autophagy and proteasomal activity, two key pathways involved in MHC-I degradation. This dual inhibition stabilizes MHC-I molecules, leading to enhanced tumor antigen presentation and improved recognition by CD8+ T cells. In co-culture systems, tetrandrine treatment increased CD8+ T cell activation and cytotoxicity against melanoma cells, evidenced by elevated IFN-γ secretion and increased tumor cell apoptosis. Administration of tetrandrine (50 mg·kg-1·d-1, i.g., for 15 days) significantly suppressed melanoma growth in mouse models accompanied by increased CD8+ T cell infiltration and activation within the tumor microenvironment. Notably, tetrandrine synergized with anti-PD-1 immune checkpoint therapy, leading to enhanced tumor growth inhibition compared to either treatment alone. We revealed that tetrandrine (7.5 μM) blocked the lysosomal calcium efflux channel TPC2, disrupting lysosomal calcium homeostasis, thus impairing lysosomal acidification and proteasomal activity, thereby stabilizing MHC-I molecules and promoting antigen presentation. These results highlight tetrandrine’s unique mechanism of action in enhancing MHC-I-mediated antigen presentation through dual inhibition of autophagic flux and proteasomal degradation. This study underscores tetrandrine’s potential as a novel immunomodulatory agent to boost CD8+ T cell-mediated tumor cell eradication and enhance the efficacy of immune checkpoint therapies.
- 29 August 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 337 (Pt 1) , 118765
Integrated metabolomics and network pharmacology to reveal the mechanisms of Processed Aurantii Fructus in the treatment of CUMS-induced functional dyspepsia
- 29 August 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 337 (Pt 1) , 118765
Integrated metabolomics and network pharmacology to reveal the mechanisms of Processed Aurantii Fructus in the treatment of CUMS-induced functional dyspepsia
- 7 September 2023
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 477, 116679
Identification of Fangchinoline as a novel autophagy inhibitor with an adjuvant of chemotherapy against lung cancer
- 7 September 2023
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 477, 116679
Identification of Fangchinoline as a novel autophagy inhibitor with an adjuvant of chemotherapy against lung cancer
- 2 February 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 307, 116216
Pathway network-based quantitative modeling of the time-dependent and dose-response anti-inflammatory effect of Reduning Injection
- 2 February 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 307, 116216
Pathway network-based quantitative modeling of the time-dependent and dose-response anti-inflammatory effect of Reduning Injection
- 7 September 2022
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 39 (4) , 1297-1317
Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells
Autophagy is typically activated in cancer cells as a rescue strategy in response to cellular stress (e.g., chemotherapy). Herein, we found that Berbamine Hydrochloride (Ber) can act as an effective inhibitor of the late stage of autophagic flux, thereby potentiating the killing effect of chemotherapy agents. Lung carcinoma cells exposed to Ber exhibited increased autophagosomes, marked by LC3-II upregulation. The increased level of p62 after Ber treatment indicated that the autophagic flux was blocked at the late stage. The lysosome staining assay and cathepsin maturation detection indicated impaired lysosomal acidification. We found that Nox2 exhibited intensified co-localization with lysosomes in Ber-treated cells. Nox2 is a key enzyme for superoxide anion production capable of transferring electrons into the lysosomal lumen, thereby neutralizing the inner protons; this might explain the aberrant acidification. This hypothesis is further supported by the observed reversal of lysosomal cathepsin maturation by Nox2 inhibitors. Finally, Ber combined with cisplatin exhibited a synergistic killing effect on lung carcinoma cells. Further data suggested that lung carcinoma cells co-treated with Ber and cisplatin accumulated excessive reactive oxygen species (ROS), which typically activated MAPK-mediated mitochondria-dependent apoptosis. The enhanced anti-cancer effect of Ber combined with cisplatin was also confirmed in an in vivo xenograft mouse model. These findings indicate that Ber might be a promising adjuvant for enhancing the cancer cell killing effect of chemotherapy via the inhibition of autophagy. In this process, Nox2 might be a significant mediator of Ber-induced aberrant lysosomal acidification. Graphical abstract
- 7 September 2022
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 39 (4) , 1297-1317
Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells
Autophagy is typically activated in cancer cells as a rescue strategy in response to cellular stress (e.g., chemotherapy). Herein, we found that Berbamine Hydrochloride (Ber) can act as an effective inhibitor of the late stage of autophagic flux, thereby potentiating the killing effect of chemotherapy agents. Lung carcinoma cells exposed to Ber exhibited increased autophagosomes, marked by LC3-II upregulation. The increased level of p62 after Ber treatment indicated that the autophagic flux was blocked at the late stage. The lysosome staining assay and cathepsin maturation detection indicated impaired lysosomal acidification. We found that Nox2 exhibited intensified co-localization with lysosomes in Ber-treated cells. Nox2 is a key enzyme for superoxide anion production capable of transferring electrons into the lysosomal lumen, thereby neutralizing the inner protons; this might explain the aberrant acidification. This hypothesis is further supported by the observed reversal of lysosomal cathepsin maturation by Nox2 inhibitors. Finally, Ber combined with cisplatin exhibited a synergistic killing effect on lung carcinoma cells. Further data suggested that lung carcinoma cells co-treated with Ber and cisplatin accumulated excessive reactive oxygen species (ROS), which typically activated MAPK-mediated mitochondria-dependent apoptosis. The enhanced anti-cancer effect of Ber combined with cisplatin was also confirmed in an in vivo xenograft mouse model. These findings indicate that Ber might be a promising adjuvant for enhancing the cancer cell killing effect of chemotherapy via the inhibition of autophagy. In this process, Nox2 might be a significant mediator of Ber-induced aberrant lysosomal acidification. Graphical abstract